We have found that SGLTIs may display advantage vs other oral agents in relation to HbA1C outcome. Serious consideration should be given to their use (Diabetes, Obesity and Metabolism)
Diabetes News
Tag: SGLT2 inhibitors
Different Glucagon Effects During DPP-4 Inhibition versus SGLT-2 Inhibition in Metformin-Treated Type 2 Diabetes Subjects
We conclude that treatment with DPP-4 inhibition with vildagliptin results in 15% lower fasting and postprandial glucagon levels compared to SGLT-2 inhibition with dapagliflozin. DPP-4 inhibition also induces a more rapid insulin secretion and higher levels of intact incretin hormones resulting in stronger feedback inhibition of incretin hormone secretion than SGLT-2 inhibition (Diabetes, Obesity and Metabolism)
Different Glucagon Effects During DPP-4 Inhibition versus SGLT-2 Inhibition in Metformin-Treated Type 2 Diabetes Subjects
We conclude that treatment with DPP-4 inhibition with vildagliptin results in 15% lower fasting and postprandial glucagon levels compared to SGLT-2 inhibition with dapagliflozin. DPP-4 inhibition also induces a more rapid insulin secretion and higher levels of intact incretin hormones resulting in stronger feedback inhibition of incretin hormone secretion than SGLT-2 inhibition (Diabetes, Obesity and Metabolism)
Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10)
Dulaglutide as add-on treatment to SGLT2 inhibitors (with or without metformin) resulted in significant and clinically relevant improvements in glycaemic control, with acceptable tolerability that is consistent with the established safety profile of dulaglutide (The Lancet Diabetes & Endocrinology)
Short and medium-term efficacy of sodium glucose co-transporter-2 (SGLT-2) inhibitors: A meta-analysis of randomized clinical trials
SGLT-2 inhibitors showed a good persistence of efficacy, at least up to 2 years, with a small but significant superiority over DPP-4i. Sulfonylureas are more effective in the very short term, but less effective in the longer term (Diabetes, Obesity and Metabolism)
Safety and Efficacy of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors in Type 1 Diabetes: A Systematic Review and Meta-Analysis
The current study lends supports for the development of SGLT2 inhibitors in combination with insulin as a treatment option for patients with type 1 diabetes (Diabetes Research and Clinical Practice)
SGLT2 inhibitors with cardiovascular benefits: transforming clinical care in Type 2 diabetes mellitus
SGLT2 inhibitors have the potential to transform the clinical care of persons with T2DM by not only improving glycaemic control but also reducing blood pressure, body weight and diabetes-related end-organ complications (Diabetes Research and Clinical Practice)
No disparity of the efficacy and all cause mortality between Asian and non-Asian type 2 diabetes patients with SGLT2 inhibitors treatment: A meta-analysis
Overall, according to this meta-analysis, comparison of the efficacy in SGLT2 inhibitors treatment between Asian and non-Asian type 2 diabetes patients indicated no significant difference in HbA1c reduction and body weight reduction (Journal of Diabetes Investigation)
Cost of Glycemic Target Achievement with Sodium Glucose Co-transporter 2 Inhibitors in Patients with Type 2 Diabetes in the UK
This analysis suggests that, in the UK, canagliflozin 300 mg provides the best value for money among all SGLT2 inhibitors in terms of achieving HbA1c <7.0% when used as part of triple therapy with metformin plus sulfonylurea (Diabetes Therapy)
Heart failure hospitalization risk associated with use of two classes of oral antidiabetic medications: an observational, real-world analysis
In this real-life analysis, the rate of hospitalizations for heart failure was significantly lower for patients initiating an SGLT2 compared with a DPP4 medication, specifically among older patients and those with diabetes complication (Cardiovascular Diabetology)
Rationale, Design, and Baseline Characteristics of the Utopia Trial for Preventing Diabetic Atherosclerosis Using an SGLT2 Inhibitor: A Prospective, Randomized, Open-Label, Parallel-Group Comparative Study
Our study is expected to provide clinical data that will be helpful in the prevention of diabetic atherosclerosis and subsequent cardiovascular and cerebrovascular disease (Diabetes Therapy)
Acute Kidney Injury in Patients on SGLT2 Inhibitors: A Propensity-Matched Analysis
Our findings do not suggest an increased risk of AKI associated with SGLT2 inhibitor use in patients with T2D in two large health systems (Diabetes Care)
Early effects of sodium-glucose co-transporter 2 inhibitors in type 2 diabetes: study based on continuous glucose monitoring
The results showed that the SGLT2 inhibitors lower blood glucose from 2 h after the first dose and improve blood glucose variation by week 1 after start of the treatment. Furthermore, SGLT2 inhibitors did not alter the incidence of hypoglycemic episodes at week 1, suggesting that SGLT2 protects against severe hypoglycemia by inhibiting urinary glucose excretion (Diabetology & Metabolic Syndrome)
Glucose-lowering drugs: balancing risks and benefits
Yet more evidence in support of a class effect of SGLT2 inhibitors (The Lancet Diabetes & Endocrinology)
Sodium-Glucose Cotransporter-2 Inhibition Improves Incretin Sensitivity of Pancreatic β-cells in Patients with Type 2 Diabetes
Dapagliflozin improved β-cell responses to incretin hormones as well as glucose during the hyperglycemic clamp in patients with inadequately controlled T2DM (Diabetes, Obesity and Metabolism)
Early effects of sodium-glucose co-transporter 2 inhibitors in type 2 diabetes: study based on continuous glucose monitoring
The results showed that the SGLT2 inhibitors lower blood glucose from 2 h after the first dose and improve blood glucose variation by week 1 after start of the treatment. Furthermore, SGLT2 inhibitors did not alter the incidence of hypoglycemic episodes at week 1, suggesting that SGLT2 protects against severe hypoglycemia by inhibiting urinary glucose excretion (Diabetology & Metabolic Syndrome)
Use of SGLT2 inhibitors for diabetes and risk of infection: Analysis using general practice records from the NPS MedicineWise MedicineInsight program
Similar to existing evidence, we found a higher risk of genital infection associated with SGLT2 inhibitors (primarily dapagliflozin) but no increased risk of UTIs compared to DPP-4 use (Diabetes Research and Clinical Practice)
SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease
All the researches, mentioned in this paper, demonstrating the SGLT2 inhibitors with their novel mechanism and associated benefits on glucose-lowering, renoprotection, body weight, CV safety, etc. have proved to be promising choices either as monotherapy or as combination therapy for patients with DKD (Cardiovascular Diabetology)
Lack of Evidence for a Harmful Effect of Sodium–Glucose Cotransporter 2 (SGLT2) Inhibitors on Fracture Risk among Type 2 Diabetes Patients
Our meta-analysis based on available RCT data does not support the harm effect of SGLT2 inhibitors on fracture, although future safety monitoring from RCT and real-world data with detailed information on bone health is warranted (Diabetes, Obesity and Metabolism)
Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis
These data suggest net protection of SGLT2 inhibitors against cardiovascular outcomes and death (The Lancet Diabetes & Endocrinology)
Glycosmedia is also available as an App: